DT.BIOTECH INNOV.AG O.N.
Save
–
Market cap
–
Current P/E
–
Forward P/E
About
Deutsche Biotech Innovativ AG operates as a biotechnology company in Germany. The company develops Adrecizumab, an antibody-based therapy that has completed the Phase I/II clinical trial for the treatment of septic shock. It also focuses on the development of various drugs for the treatment of solid tumor, organ failure, rosacea, neurodermatitis, pharyngitis, and Alzheimer's diseases.
Similar securities
Based on sector and market capitalization
Report issue